@2024 - All Right Reserved.

COPENHAGEN, Denmark — Novo Nordisk sued Hims and Hers Health on Monday over alleged patent infringement after the U.S. telehealth firm launched, then canceled, a $49 copy of Novo's weight-loss pill ...

The U.S. Food and Drug Administration said a television advertisement for Novo Nordisk's weight-loss pill is "false or misleading," according to a letter dated February 5. The health regulator said ...

Novo Nordisk stock surged after Hims & Hers scrapped plans to sell a copycat version of the drugmaker’s weight-loss pill following pressure from U.S. regulators. Shares in Novo Nordisk jumped nearly 7 ...

Novo Nordisk said it filed a federal lawsuit Feb. 9 against telehealth provider Hims & Hers, alleging the company infringed on Novo's patent by selling versions of its blockbuster weight-loss drug ...

Hims & Hers will pull its compounded semaglutide pill after legal threats from Novo Nordisk and warnings from the FDA over illegal mass compounding. Catherine O'Hara's cause of death revealed Trump ...

The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss ...

View post: I'm a Strength Coach—This is the One Piece of Workout Equipment I Wish All Men Over 50 Owned I'm a Strength Coach—This is the One Piece of Workout Equipment I Wish All Men Over 50 Owned ...

Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug and one day after the Food and Drug ...